60 citations,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
38 citations,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
3 citations,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
84 citations,
February 2015 in “Experimental Dermatology” PPARγ is crucial for skin health but can have both beneficial and harmful effects.
July 2022 in “Research Square (Research Square)” This study involving 93 Egyptian female patients with Frontal Fibrosing Alopecia (FFA) and 157 healthy controls found that FFA patients had significantly lower serum levels of Peroxisome Proliferator Activated Receptors Gamma (PPARγ) and a higher prevalence of the PPARG (Pro12Ala) gene polymorphism. These genetic variations were linked to reduced PPARγ levels and increased FFA severity, suggesting that PPARγ could be a crucial biomarker for FFA. Although the study indicates the potential of PPARγ agonists in treating FFA, it could not evaluate their therapeutic efficacy due to patient compliance issues.